Skip to main content

Johnson & Johnson vs Pfizer: Revenue, Profit and Business Model

Johnson & Johnson had $94.2B of annual revenue in FY2025 and $26.8B of net income. Pfizer had $62.6B of annual revenue in FY2025 and $7.8B of net income.

Latest financial snapshot

Johnson & Johnson

Latest annual revenue
$94.2B (FY2025)
Net income
$26.8B
Net margin
28.5%
Revenue growth
+3.0% a year, FY2016–FY2025

Pfizer

Latest annual revenue
$62.6B (FY2025)
Net income
$7.8B
Net margin
12.4%
Revenue growth
+1.9% a year, FY2016–FY2025

Financial summary

Johnson & Johnson

J&J's sales grew from $85.2 billion in 2023 to $88.8 billion in 2024 and $94.2 billion in 2025, while FY2025 net earnings reached $26.8 billion. Q2 2026 sales were $25.31 billion (Innovative Medicine $16.38 billion, MedTech $8.93 billion), net earnings were $5.53 billion, adjusted EPS was $2.90, and first-half free cash flow was about $8.7 billion. Management guides 2026 sales of $100.8 to $101.4 billion and adjusted EPS of $11.60 to $11.75. The company has raised its dividend for more than 60 consecutive years, and its market value was roughly $644 billion in mid-September 2026. Johnson & Johnson is a healthcare juggernaut, maintaining a massive market valuation often exceeding $350 billion.

Pfizer

Pfizer revenue rose from $41.7 billion in 2020 to $81.3 billion in 2021 and $101.2 billion in 2022 on Comirnaty and Paxlovid, then fell to $59.6 billion in 2023 as COVID demand collapsed. It recovered to $63.6 billion in 2024 and was $62.6 billion in 2025, with net income of $7.8 billion. In Q2 2026 revenue was $15.0 billion, up 1% operationally, or 5% excluding COVID products, and Pfizer raised the midpoint of its 2026 revenue guidance to $60.5 billion to $62.5 billion with adjusted EPS guidance of $2.80 to $3.00. The roughly $31 billion of debt raised for Seagen in 2023 and an ongoing cost-reduction program shape capital allocation alongside a dividend yield near 6%. Pfizer ranks among the largest pharmaceutical companies in the world, carrying a market valuation typically exceeding $150 billion.

Revenue and profit by year

Johnson & Johnson

Johnson & Johnson revenue, net income, margin and growth by fiscal year
YearRevenueNet incomeMarginGrowthSource
FY2025$94.2B$26.8B28.5%+6.0%Source
FY2024$88.8B$14.1B15.8%+4.3%Source
FY2023$85.2B$35.2B41.3%+6.5%Source
FY2022$80B$17.9B22.4%+1.6%Source
FY2021$78.7B$20.9B26.5%-4.7%Source
FY2020$82.6B$14.7B17.8%+0.6%Source
FY2019$82.1B$15.1B18.4%+0.6%Source
FY2018$81.6B$15.3B18.8%+6.7%Source
FY2017$76.5B$1.3B1.7%+6.3%Source
FY2016$71.9B$16.5B23.0%—Source
Full Johnson & Johnson financials

Pfizer

Pfizer revenue, net income, margin and growth by fiscal year
YearRevenueNet incomeMarginGrowthSource
FY2025$62.6B$7.8B12.4%-1.6%Source
FY2024$63.6B$8B12.6%+6.8%Source
FY2023$59.6B$2.1B3.6%-41.1%Source
FY2022$101.2B$31.4B31.0%+24.5%Source
FY2021$81.3B$22B27.0%+95.2%Source
FY2020$41.7B$9.2B22.0%+1.8%Source
FY2019$40.9B$16B39.2%+0.2%Source
FY2018$40.8B$11.2B27.3%-22.3%Source
FY2017$52.5B$21.3B40.6%-0.5%Source
FY2016$52.8B$7.2B13.7%—Source
Full Pfizer financials

Where the revenue comes from

Johnson & Johnson

  • Innovative Medicine~64%

    Innovative Medicine generated $60.401 billion in FY2025 sales across oncology, immunology, neuroscience, pulmonary hypertension, infectious disease, and cardiovascular/metabolism.

  • MedTech~36%

    MedTech generated $33.792 billion in FY2025 sales across surgery, orthopaedics, cardiovascular, and vision products.

Pfizer

  • Patented medicines

    Core revenue

    Prescription drugs protected by exclusivity and clinical differentiation.

  • Vaccines

    Major revenue contributor

    Adult, pediatric, pneumococcal, RSV, and COVID-related vaccines.

  • Oncology

    Strategic growth driver

    Cancer medicines, antibody-drug conjugates, and Seagen-related assets.

  • Hospital and anti-infective products

    Meaningful contributor

    Sterile injectables, anti-infectives, and hospital therapies.

  • Collaborations and alliances

    Supplemental

    Co-promoted products and partnered scientific platforms.

Business model and strategy

Johnson & Johnson

How it makes money

Johnson & Johnson is a global healthcare titan that operates through two focused, high-margin divisions following the successful corporate spinoff of its consumer health business (Kenvue): Innovative Medicine and MedTech.

Growth strategy

J&J is narrowing its portfolio toward higher-growth areas. It spun off consumer health as Kenvue in 2023, announced in October 2025 that it will separate its orthopaedics business as DePuy Synthes, and used acquisitions to refill its pipeline: Abiomed ($16.6 billion, 2022), Shockwave Medical ($13.1 billion, 2024), and Intra-Cellular Therapies ($14.6 billion, 2025).

Competitive advantage

Johnson & Johnson's durable competitive moat is built upon its dual-pillar enterprise architecture, unmatched hospital procurement distribution channels, and an elite AAA-rated corporate balance sheet shared with only one other public company globally.

Johnson & Johnson business model in full

Pfizer

How it makes money

Pfizer Inc. is a research-based global biopharmaceutical company that discovers, develops, manufactures, and commercializes innovative prescription medicines, vaccines, and cellular therapies. Pfizer's commercial model operates across several primary therapeutic areas: Oncology, Vaccines, Internal Medicine, Hospital and Anti-Infectives, and Inflammation & Immunology.

Growth strategy

Pfizer's growth plan has three parts. Oncology: the $43 billion Seagen deal (closed December 2023) added Padcev, Adcetris, Tukysa and Tivdak, and Pfizer licensed 3SBio's PD-1xVEGF bispecific in 2025 and signed a 12-program cancer collaboration with Innovent Biologics in May 2026 ($650 million upfront, up to $10.5 billion total).

Competitive advantage

Pfizer's economic moat is rooted in its immense global clinical trial scale, unmatched commercial distribution infrastructure, and specialized aseptic vaccine manufacturing capabilities.

Pfizer business model in full

Questions about Johnson & Johnson vs Pfizer

Which company has higher revenue — Johnson & Johnson or Pfizer Inc.?

Johnson & Johnson had $94.2B (FY2025), while Pfizer Inc. had $62.6B (FY2025). By latest annual revenue, Johnson & Johnson is the larger business, with Pfizer Inc. showing a smaller revenue base.

What is the market cap of Johnson & Johnson vs Pfizer Inc.?

Johnson & Johnson's market capitalisation stands at $643.9B, while Pfizer Inc.'s is $160.3B. Johnson & Johnson carries the higher market valuation, reflecting investors' expectations of its future earnings power relative to Pfizer Inc..

How does revenue per employee compare for Johnson & Johnson and Pfizer Inc.?

Johnson & Johnson has $669k / employee in revenue per employee, while Pfizer Inc. has $834k / employee. Headcounts may use different dates, so the ratio alone does not establish which business operates more efficiently.

How do Johnson & Johnson and Pfizer Inc. make money?

Johnson & Johnson and Pfizer Inc. generate revenue in fundamentally different ways. Johnson & Johnson: Johnson & Johnson is a global healthcare titan that operates through two focused, high-margin divisions following the successful corporate spinoff of its consumer health business (Kenvue): Innovative Medicine and MedTech. Pfizer Inc.: Pfizer Inc. is a research-based global biopharmaceutical company that discovers, develops, manufactures, and commercializes innovative prescription medicines, vaccines, and cellular therapies.

Which company is valued higher relative to revenue — Johnson & Johnson or Pfizer Inc.?

On a price-to-sales (P/S) basis, Johnson & Johnson trades at 6.8x P/S and Pfizer Inc. at 2.6x P/S. Johnson & Johnson commands a higher revenue multiple, typically indicating that investors expect faster growth or higher future margins compared to Pfizer Inc.. A higher multiple is not inherently better — it may also signal that the stock is priced for perfection.

Is Johnson & Johnson bigger than Pfizer Inc.?

By last reported revenue, Johnson & Johnson ($94.2B (FY2025)) is the larger company compared to Pfizer Inc. ($62.6B (FY2025)). Revenue scale is one dimension of size — market capitalisation, employee count, and geographic reach are also relevant depending on the context.

Figures come from each company's filings and the sources linked beside them. Amounts reported in another currency are shown in US dollars at an approximate rate and marked with ~. Back to the Johnson & Johnson vs Pfizer overview

Content is for informational purposes only. Not financial advice. Data sourced from SEC filings, annual reports, and public records. See our full disclaimer and methodology.